AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04791228
Drug: Lyso-thermosensitive Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTLD combines doxorubicin with lyso-thermosensitive liposomes that can selectively deliver drug to tumors and when exposed to temperatures greater than 40°C, rapidly and locally releases doxorubicin in high concentrations from systemically administered LTLD.~If combined with hyperthermia, doxorubicin will be released in the heated tumor margins and in any areas within the tumor that were not completely ablated and increase the likelihood of complete tumor necrosis. LTLD will extend tumor cell death to the hyperthermic regions in the peri-ablation zones and minimize the possibility of incomplete ablation or tumor recurrence.
Trial: NCT05442827
Drug: SHR7280 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR7280 tablets 300mg for 12 weeks
Trial: NCT05442827
Drug: SHR7280 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR7280 tablets 400mg for 12 weeks
Trial: NCT05442827
Drug: PlaceboSHR7280 tablets blank preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group: SHR7280 tablets blank preparation for 12 weeks
Trial: NCT06135298
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (ZA), is a bisphosphonate, and has been shown to reduce the risk of hip fracture by 41% in post-menopausal women. For systemic injection, 5 mg (as per clinical protocol) will be injected intravenously 5 days after surgery, during hospitalization.
Trial: NCT06286189
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule taken 30 min before sleep
Trial: NCT04576988
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered subcutaneously (SC) every 21 days plus background PAH therapy.
Trial: NCT04576988
Drug: Background PAH Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Background PAH therapy may consist of the following drug classes: an endothelin-receptor antagonist (ERA), a phosphodiesterase 5 (PDE5) inhibitor, a soluble guanylate cyclase stimulator, and/or a prostacyclin analogue or receptor agonist.
Trial: NCT06434610
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: The subjects will receive IV dose of placebo matched to B013 on Day 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.
Trial: NCT04408989
Drug: MB02-SP
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
Trial: NCT04408989
Drug: US licenced Avastin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
Trial: NCT04246151
Drug: Probiotic Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pill manufactured to mimic 10 billion unit probiotic capsules.
Trial: NCT05488678
Drug: VNRX-7145
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose
Trial: NCT06376201
Drug: Amphotericin B cholesterol-sulfate complex for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were eligible for enrollment on antifungal therapy with injectable amphotericin B cholesterol-sulfate complex (ABCD) at the same time as a treatment for underlying disease.~Dosage: According to the patient's condition and the investigator's judgment, the initial dose of ABCD can be 0.5-1.0mg/kg/d, and the dose can be increased daily according to the situation, and the therapeutic dose can be increased to 3.0-4.0mg/kg/d on the third day.~Course of treatment: ≥ 14 days (whether to continue to receive trial drug treatment after 14 days is decided by the investigator according to the patient's condition).
Trial: NCT06026527
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml Normal Saline will be infused intravenously over 20-30 minutes in the participants allocated to control group starting from the moment of induction of anaesthesia
Trial: NCT06752746
Drug: 9MW3011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose
Trial: NCT05631574
Drug: BMF-219
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.
Trial: NCT04703101
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04703101
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04703101
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06118281
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to ziltivekimab will be adminsitered subcutaneously as an initial loading dose followed by a maintenance dose once-monthly.
Trial: NCT04836559
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally.
Trial: NCT04995523
Drug: AZD2936
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TIGIT/Anti-PD-1 Bispecific Antibody
Trial: NCT05375461
Drug: TQB3616 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of TQB3616 capsules is 180mg, taken orally on an empty stomach, once a day for 28 consecutive days as one treatment cycle.
Trial: NCT05375461
Drug: TQB3616-matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of placebo is 180mg, taken orally on an empty stomach, once a day for 28 consecutive days as one treatment cycle.
Trial: NCT05375461
Drug: Fluvestrin injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvestrin injection was given at a fixed dose of 500mg on day 1, day 15 of the first treatment cycle and day 1 of each subsequent treatment cycle, and a treatment cycle of 28 days.
Trial: NCT06022029
Drug: ONM-501
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratumoral injection
Trial: NCT06780410
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, oral
Trial: NCT06157216
Drug: MRD-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRD negative stage II gastric cancer: Observation; MRD negative stage III gastric cancer: S1 (40-60 mg, PO, bid, d1-d14 q3w); MRD positive stage II/III gastric cancer: XELOX (Oxaliplatin 130mg/m2, d1 +Capecitabine 1000mg/m2，PO. bid, d1-14, q3w) or SOX (Oxaliplatin 130mg/m2, d1 +S-1 40-60 mg, PO. bid, d1-14, q3w); MRD-negative patients will receive XELOX or SOX if MRD becomes positive.
Trial: NCT05607446
Drug: TQC3564 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQC3564 tablets are CRTH2 antagonists.
Trial: NCT05607446
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention drug is placebo.
Trial: NCT05038306
Drug: Chinese medicine WT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Chinese medicine WT is thought to be neurotrophic, and its major constituent may benefit IGF-1 in animal studies, or certain healthy human group. WT is safe in clinical use in Asia.
Trial: NCT04643158
Drug: AZD1402
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomised participants will receive oral inhalation of AZD1402, via DPI.
Trial: NCT04643158
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomised participants will receive oral inhalation of matching placebo via DPI.
Trial: NCT04643158
Drug: Short acting beta agonist (SABA) (rescue medication)
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In addition to study intervention, all participants will be provided with a SABA as rescue medication (eg, salbutamol/albuterol), to be used throughout the Run-in and Treatment Periods. All participants should refrain from taking a SABA as rescue medication 6 hours prior to pulmonary function tests.~Dosage levels: 100 μg per nominal dose 90 μg per nominal dose pro re nata (as required) (PRN)
Trial: NCT06182839
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will get 1 pill of placebo daily for one year.
Trial: NCT06764836
Drug: IMM27M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection
Trial: NCT06764836
Drug: IMM2510
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection
Trial: NCT05064449
Drug: Mefenamic acid
RxNorm normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mefenamic acid capsule.
Trial: NCT05994690
Drug: Standard Intervention Rc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 consolidation courses (HAM + HA3E + FLA)
Trial: NCT05994690
Drug: Investigational Intervention Ri
RxNorm normalized name: Ri-Mag Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of GO to first induction course
Trial: NCT05751850
Drug: HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR070803 in combination with oxaliplatin, 5-fluorouracil, calcium folinate
Trial: NCT05546515
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be prescribed up to 30 days of placebo medication.
Trial: NCT05917938
Drug: NNC0194-0499
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNC0194-0499 will be administered subcutaneously in a skinfold in the thigh in the form of a solution for injection.
Trial: NCT06368440
Drug: AZD6793
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive AZD6793 multiple doses daily as oral suspension.
Trial: NCT06368440
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching doses of placebo as oral suspension.
Trial: NCT06614881
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: loading dose of saline was injected 10-min before induction of anesthesia.
Trial: NCT05845424
Drug: Guideline directed statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At least moderate intensity statin, recommended by the current guideline based on the ASCVD risk
Trial: NCT05215847
Drug: ARD-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily, oral administration
Trial: NCT05370495
Drug: SY-201 Ophthalmic Solution 2.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SY-201 Ophthalmic Solution 2.0%
Trial: NCT05370495
Drug: SY-201 Ophthalmic Solution 1.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SY-201 Ophthalmic Solution 1.0%
Trial: NCT05370495
Drug: SY-201 Ophthalmic Solution 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SY-201 Ophthalmic Solution 0.5%
Trial: NCT04231708
Drug: Yohimbine + Hydrocortisone
RxNorm normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (54mg bulk powder inside capsule) administered in combination with Hydrocortisone (20mg tablet inside capsule)
Trial: NCT04231708
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lactose (inside capsule)
Trial: NCT06009653
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo subcutaneous injections.
Trial: NCT06541574
Drug: Methotrexate Injection
RxNorm normalized name: methotrexate Injection
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate injection
Trial: NCT05453552
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3,-2.
Trial: NCT06541574
Drug: Methotrexate Infusion
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate Infusion
Trial: NCT05134012
Drug: [O-15]-Water PET Myocardial Perfusion Imaging (MPI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[15-O\]-H2O injection is a novel PET imaging agent labeled with the radioisotope \[15-O\] administered as an intravenous (IV) injection. Participants will receive \[15-O\]-H2O treatment twice as a part of a single day imaging session. All participants will receive two IV boluses of \[15-O\]-H2O injection in a peripheral vein; one at rest and one during pharmacological stress.
Trial: NCT06587698
Drug: BeiDouGen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg BID for 3 month
Trial: NCT05279755
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral solution
Trial: NCT06589752
Drug: TARPEYO 4 MG Delayed Release Oral Capsule
RxNorm normalized name: Tarpeyo 4 MG Delayed Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TARPEYO dispensing claim for any dose is exposure
Trial: NCT06589752
Drug: RAS inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RASi dispensing claim for any dose is reference
Trial: NCT06272487
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered by SC injection
Trial: NCT04409080
Drug: REGN7257
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravenous (IV) infusion, in Part A and B.
Trial: NCT05945537
Drug: INI-822 (A)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different dose levels of INI-822
Trial: NCT05175352
Drug: CYP substrates
RxNorm normalized name: estradiol cypionate / testosterone cypionate Injectable Solution [Duo-Cyp]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05601219
Drug: ADA-011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADA-011 will be administered intravenously (IV) Q3W on a 21-day cycle.
Trial: NCT05601219
Drug: PD(L)-1 inhibitor
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD(L)-1 inhibitor will be administered intravenously (IV) Q3W.
Trial: NCT05687903
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablets matching TAK-861
Trial: NCT04720456
Drug: SHAPE measurement using the ultrasound contrast agent Sonazoid (perfluorobutane microbubbles)
RxNorm normalized name: ULTRASOUND CONTRAST MEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The ultrasound contrast agent will be infused thorough an IV line and SHAPE ultrasound imaging and data acquisition will be performed with a Logiq E10 (GE Medical Systems, Waukesha, WI) ultrasound scanner.
Trial: NCT04720456
Drug: SHAPE measurement using the ultrasound contrast agent Lumason (sulfur hexafluoride lipid-type A microspheres)
RxNorm normalized name: ULTRASOUND CONTRAST MEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The ultrasound contrast agent will be infused thorough an IV line and SHAPE ultrasound imaging and data acquisition will be performed with a Logiq E10 (GE Medical Systems, Waukesha, WI) ultrasound scanner.
Trial: NCT06704893
Drug: ASA injection 40 mg group
RxNorm normalized name: meningococcal group B vaccine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive intra-articular knee injections under ultrasound guidance with AMNIOGEN® 40mg (HCT Regenerative, New Taipei, Taiwan) diluted in 3.0 mL of sterile normal saline.
Trial: NCT06704893
Drug: ASA injection 20 mg group
RxNorm normalized name: meningococcal group B vaccine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive intra-articular knee injections under ultrasound guidance with AMNIOGEN® 20mg (HCT Regenerative, New Taipei, Taiwan) diluted in 3.0 mL of sterile normal saline.
Trial: NCT06704893
Drug: HA injection group
RxNorm normalized name: meningococcal group B vaccine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive intra-articular knee injections under ultrasound guidance with 3 ml of HyLink (SEIKAGAKU CORPORATION, Tokyo, Japan).
Trial: NCT06275919
Drug: Local Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this setting there are not drugs with indication. Every site will treat patients as per their experience.
Trial: NCT05328557
Drug: CUG252
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CUG252 will be administered by subcutaneous (SC) injection
Trial: NCT05328557
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered by subcutaneous (SC) injection
Trial: NCT05832229
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients meeting all eligibility criteria will be assigned to a randomization arm prior to initiation of a 4-week lead-in phase of the study. All participants will undergo a 4-week, open-label active run-in phase to evaluate initial safety and adherence to rosuvastatin. During this active run-phase, all participants will receive target dose rosuvastatin-- 20 mg daily (10 mg daily for participants of East-Asian ancestry or on a protease inhibitor). After the active run-in phase, all participants will continue with their pre-assigned randomization (1:1) treatment of rosuvastatin 20 mg daily (10 mg daily for participants of East-Asian ancestry or on a protease inhibitor) or matching placebo.
Trial: NCT06342713
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05470205
Drug: SHAPE measurement (Sonazoid ultrasoud contrast agent)
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
Trial: NCT05470205
Drug: SHAPE measurement (Definity ultrasoud contrast agent)
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two vials with 3 mL of Definity will be mixed and diluted in 50 mL of normal saline, yielding a concentration of 49.4 μL/mL, and infused at a rate of at least 4 ml/min.
Trial: NCT04989699
Drug: OTX-TKI/Sham
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTX-TKI is one dose so subsequent visits will be sham to maintain the mask
Trial: NCT06704581
Drug: 5 mg BGM0504 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg BGM0504 injection administered subcutaneously (SC) once a week.
Trial: NCT06704581
Drug: 15 mg BGM0504 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg BGM0504 injection administered subcutaneously (SC) once a week.
Trial: NCT06704581
Drug: BGM0504 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGM0504 placebo administered SC once a week.
Trial: NCT06056596
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose to be taken once daily for three days (two days prior to surgery and on the morning of surgery)
Trial: NCT05607030
Drug: SOC Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of at least 6 weeks of systemic antibiotics post-Stage 1 surgery followed by a 2-week antibiotic holiday before the Stage 2 surgery. After Stage 2 surgery, administration of at least 12 weeks of systemic antibiotics. Antibiotics will be selected by the treatment provider based on the infecting organism and administered per national and local treatment guidelines.
Trial: NCT05607030
Drug: Experimental Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After Stage 2 surgery, administration of at least 12 weeks of systemic antibiotics. Antibiotics will be selected by the treatment provider based on the infecting organism and administered per national and local treatment guidelines.
Trial: NCT06472583
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0,9% NaCl in the volume 100 ml
Trial: NCT05925803
Drug: Placebo (blinded)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched placebo delivered subcutaneously, once weekly for 52 weeks
Trial: NCT06507306
Drug: KQB198
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral KQB198
Trial: NCT06229145
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral
Trial: NCT06290102
Drug: TEV-56248
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Dry powder~Route of administration: Oral inhalation
Trial: NCT06034197
Drug: VGT-309
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.32mg/kg IV of VGT-309 given 12-36 hours before surgery
Trial: NCT06467084
Drug: KVD900 75 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KVD900 Tablet 75 mg (1 x 75 mg)
Trial: NCT06467084
Drug: KVD900 150 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KVD900 Tablet 150 mg (2 x 75 mg)
Trial: NCT06467084
Drug: KVD900 300 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KVD900 Tablet 300 mg (1 x 300 mg)
Trial: NCT04557462
Drug: LNP023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule 200 mg (b.i.d.) taken orally twice a day
Trial: NCT06136741
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Injection solution Route of administration: subcutaneous
Trial: NCT04947553
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, taken twice daily
Trial: NCT05924243
Drug: RO7486967
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For up to approximately 28 days
Trial: NCT05924243
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For up to approximately 28 days